1.78
-0.06 (-3.26%)
| Previous Close | 1.84 |
| Open | 1.80 |
| Volume | 20,624 |
| Avg. Volume (3M) | 129,506 |
| Market Cap | 83,893,664 |
| Price / Sales | 829.07 |
| Price / Book | 2.29 |
| 52 Weeks Range | |
| Earnings Date | 23 Jul 2025 - 28 Jul 2025 |
| Operating Margin (TTM) | -17,082.39% |
| Diluted EPS (TTM) | -0.740 |
| Quarterly Revenue Growth (YOY) | -87.30% |
| Total Debt/Equity (MRQ) | 36.60% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | -29.70 M |
| Levered Free Cash Flow (TTM) | -18.87 M |
| Return on Assets (TTM) | -21.92% |
| Return on Equity (TTM) | -55.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Adagene Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.25 |
|
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.70% |
| % Held by Institutions | 33.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Hsg Holding Ltd | 30 Sep 2025 | 1,343,364 |
| Mill Creek Capital Advisors, Llc | 30 Sep 2025 | 199,610 |
| Kamunting Street Capital Management, L.P. | 30 Sep 2025 | 126,032 |
| Gordian Capital Singapore Pte Ltd | 30 Sep 2025 | 48,342 |
| Fifth Lane Capital, Lp | 30 Sep 2025 | 27,500 |
| 52 Weeks Range | ||
| Median | 9.00 (405.62%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 24 Nov 2025 | 9.00 (405.62%) | Buy | 1.90 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |